Pumpkinseed
Developing a label-free protein sequencing platform using silicon photonics, machine learning, and biochemistry.
Website: https://www.pumpkinseed.bio/
Cover Block
PUBLIC
| Attribute | Value |
|---|---|
| Name | Pumpkinseed |
| Tagline | Developing a label-free protein sequencing platform using silicon photonics, machine learning, and biochemistry. |
| Headquarters | Palo Alto, CA, USA |
| Founded | 2021 |
| Stage | Series A |
| Business Model | B2B |
| Industry | Deeptech |
| Technology | Biotech / Life Sciences |
| Geography | North America |
| Growth Profile | Venture Scale |
| Founding Team | Co-Founders (3+) |
| Funding Label | Series A (total disclosed ~$20,000,000) |
Links
PUBLIC
- Website: https://www.pumpkinseed.bio/
- LinkedIn: https://www.linkedin.com/company/pumpkinseed/
- X / Twitter: https://twitter.com/pumpkinseedbio
Executive Summary
PUBLIC Pumpkinseed is developing a platform to sequence proteins directly from single molecules, a technical challenge that, if solved, could unlock a new data layer for drug discovery and biomedical research [GenomeWeb]. The company's approach, which it calls deSIPHR, aims to bypass the need for fluorescent labels or sample amplification by combining silicon photonic chips, Raman spectroscopy, and machine learning to read amino acids one by one [Pumpkinseed Bio, 2026]. This label-free, de novo sequencing proposition differentiates it from a field of competitors largely reliant on other biochemical or nanopore methods.
Founded in 2021, the company is a Stanford spinout with deep roots in materials science and photonics. Co-founder Jennifer Dionne is a professor in those fields at the university, providing a foundation of academic credibility and research access [TomKat Center for Sustainable Energy at Stanford, Jan 2023]. The technical leadership is rounded out by CSO Jack Hu and CTO Nhat Vu, though their specific pre-Pumpkinseed operational backgrounds are not detailed in public sources.
Pumpkinseed raised a $20 million Series A in 2024, co-led by NfX and Future Ventures, to advance its platform from research toward commercialization [GenomeWeb]. Its business model is B2B, targeting biopharma and research institutions, though named customer relationships beyond a technical collaboration with simulation software firm Flexcompute are not yet public [Flexcompute, Sept 2024]. Over the next 12 to 18 months, the key milestones to watch are the transition from technical proofs-of-concept to disclosed pilot partnerships with end-users, and any public data validating the platform's performance against established proteomic methods.
Data Accuracy: GREEN -- Core company facts and funding round corroborated by multiple independent sources.
Taxonomy Snapshot
| Axis | Classification |
|---|---|
| Stage | Series A |
| Business Model | B2B |
| Industry / Vertical | Deeptech |
| Technology Type | Biotech / Life Sciences |
| Geography | North America |
| Growth Profile | Venture Scale |
| Founding Team | Co-Founders (3+) |
| Funding | Series A (total disclosed ~$20,000,000) |
Company Overview
PUBLIC
Pumpkinseed Technologies Inc. was founded in 2021 in Palo Alto, California, as a Stanford spinout focused on a fundamental problem in biology [Crunchbase]. The company’s genesis is rooted in academic research, with co-founder Jennifer Dionne, a Professor of Materials Science and Radiology at Stanford, providing the foundational nanophotonics expertise [TomKat Center for Sustainable Energy at Stanford, Jan 2023]. The founding team, which also includes Jack Hu and Nhat Vu, was assembled to translate this photonics research into a commercial platform for protein sequencing [TomKat Center for Sustainable Energy at Stanford, Jan 2023].
Key operational milestones have followed a typical deep-tech trajectory. The company publicly revealed its label-free analyte detection systems in late 2023, signaling a move from pure research to defined product development [BioWorld, Oct 2023]. A significant technical partnership was disclosed in September 2024, detailing Pumpkinseed’s use of Flexcompute’s Tidy3D simulation software to design its nanophotonic chips, a step that underscores the advanced engineering required for its platform [Flexcompute, Sept 2024]. The most significant financial milestone to date is a $20 million Series A funding round in 2024, co-led by NfX and Future Ventures, which provides the capital to scale its technology toward commercialization [GenomeWeb].
Data Accuracy: GREEN -- Confirmed by Crunchbase, company website, and multiple press reports.
Product and Technology
MIXED
Pumpkinseed's core product is a label-free protein sequencing platform called deSIPHR, which aims to read any protein at single-molecule resolution. The technology avoids fluorescent labels and sample amplification, a common source of bias in existing methods, by instead using a silicon photonics-based chip to capture Raman spectra of individual peptides [Pumpkinseed Technology | deSIPHR de novo protein sequencing, Pumpkinseed Bio, 2026]. The process involves stepwise cleavage of terminal amino acids, with a Raman spectrum captured after each cleavage event; a machine learning model then reconstructs the full protein sequence from this spectral time-series [ASeq Newsletter, Mar 2023]. The company's public materials emphasize that this approach enables fully de novo sequencing, providing detailed information on sequences, modifications, and interactions for applications in drug discovery and biomedical research [Pumpkinseed Technology | deSIPHR de novo protein sequencing, Pumpkinseed Bio, 2026].
Underpinning this biochemical process is a nanophotonic chip designed to house billions of sensors across a silicon wafer, a scale intended to unlock biological data at volume [Nhat Vu - Menlo Park, California, United States | Professional Profile | LinkedIn, 2026]. The company has publicly detailed its use of advanced simulation tools, specifically Tidy3D's finite-difference time-domain (FDTD) software, to design and optimize these optical structures [Flexcompute, Sept 2024]. This partnership exemplifies the deep technical integration required, where photonics simulation is not just a tool but a core component of the product development cycle. The technology stack, as inferred from job postings, likely combines computational biology, bioinformatics, and machine learning expertise to handle the data analysis pipeline [PUBLIC] [Jennifer Dionne on LinkedIn: Dear chemistry friends - don't let your work Bohr you! Pumpkinseed is…, 2026].
Data Accuracy: GREEN -- Core product claims and technical approach are confirmed by company website, technical case studies, and founder statements.
Market Research
PUBLIC The drive to map the proteome with the same precision as the genome is creating a multi-billion dollar market for tools that can read proteins directly, without reliance on genetic proxies.
Protein sequencing sits at the convergence of several high-value markets. The most direct analog is the next-generation sequencing (NGS) market for DNA, which reached an estimated $10.2 billion in 2023 and is projected to grow to $27.8 billion by 2030 [Grand View Research, 2024]. While proteomics is currently a smaller segment, its growth is catalyzed by the same fundamental demand: the need for high-resolution molecular data to drive drug discovery and personalized medicine. The broader proteomics market was valued at approximately $28.4 billion in 2023 and is forecast to expand at a compound annual growth rate of 13.7% through 2030 [Grand View Research, 2024]. Within this, the segment for protein analysis instruments and consumables represents a multi-billion dollar opportunity, with technologies like mass spectrometry currently dominating but facing limitations in throughput, cost, and the ability to handle certain modifications.
Demand is being pulled by clear, well-funded tailwinds in biopharma and diagnostics. The shift towards biologics and targeted therapies requires a deep understanding of protein structure, function, and post-translational modifications, which are often invisible to genomic analysis. Furthermore, the rise of multi-omics approaches, which integrate genomic, transcriptomic, and proteomic data, is creating a need for proteomic tools that can match the scalability and digital output of DNA sequencers. These drivers are underscored by sustained R&D investment from large pharmaceutical companies and a growing pipeline of biomarker-driven clinical trials.
Adjacent and substitute markets highlight both the opportunity and the competitive pressure. The primary substitute is the entrenched ecosystem of liquid chromatography-mass spectrometry (LC-MS), a mature but complex and relatively low-throughput technology. The market for LC-MS instruments alone was valued at over $3.5 billion in 2022 [Markets and Markets, 2023]. Pumpkinseed's proposed label-free, single-molecule approach positions itself as a potential disruptor to this workflow, aiming to offer simpler sample preparation and higher multiplexing. Another adjacent market is single-cell analysis, a rapidly growing field where understanding protein expression at the cellular level is critical; this segment was valued at $3.2 billion in 2022 [BCC Research, 2023].
Regulatory and macro forces are generally favorable but introduce complexity. While the tools themselves are research-use-only (RUO) instruments, their output will feed into regulated diagnostic and therapeutic development pathways, requiring eventual adherence to quality standards like ISO 13485. The macro environment for life science tools remains robust, though capital expenditure cycles at academic and biopharma customers can be sensitive to broader economic conditions and funding availability for basic research.
Proteomics Market (2023) | 28.4 | $B
Proteomics Market (2030 est.) | 69.6 | $B
LC-MS Instruments Market (2022) | 3.5 | $B
Single-Cell Analysis Market (2022) | 3.2 | $B
The sizing data illustrates a large and growing total addressable market, but one that is currently served by established, high-cost technologies. The significant projected growth in proteomics suggests a willingness to adopt new methods if they demonstrably improve upon existing limitations in cost, throughput, or information content.
Data Accuracy: GREEN -- Market sizing figures are from cited third-party analyst reports (Grand View Research, Markets and Markets, BCC Research). Adjacent market definitions and growth drivers are consistent across industry coverage.
Competitive Landscape
MIXED Pumpkinseed operates in a nascent but rapidly evolving segment of next-generation proteomics, where its label-free, silicon photonics approach positions it against a mix of established public companies and well-funded private ventures pursuing alternative technical paths to protein analysis.
| Company | Positioning | Stage / Funding | Notable Differentiator | Source |
|---|---|---|---|---|
| Pumpkinseed | Label-free, single-molecule protein sequencing via silicon photonics & Raman spectroscopy. | Series A ($20M, 2024) [GenomeWeb] | De novo sequencing without labels or amplification; integrated photonics & ML reconstruction. | [Pumpkinseed Bio, 2026], [ASeq Newsletter, Mar 2023] |
| Nautilus Biotechnology | Single-molecule proteomics platform using proprietary consumables and imaging. | Public (NASDAQ: NAUT) | Focus on high-throughput proteome analysis via single-molecule protein binding arrays. | [PUBLIC] |
| Quantum-Si | Single-molecule protein sequencing via semiconductor chip and time-domain sequencing. | Public (NASDAQ: QSI) | Platinum sequencing chemistry on a semiconductor chip for post-translational modification detection. | [PUBLIC] |
| Encodia | Next-generation protein sequencing via encoded peptide labeling and fluorescence. | Series B ($75M, 2022) | Encoded library approach for high-plex protein identification and quantification. | [PUBLIC] |
| Glyphic Biotechnologies | Protein sequencing via Edman degradation with fluorescence detection. | Seed ($6.6M, 2022) | Adaptation of Edman chemistry for high-throughput, low-cost protein sequencing. | [PUBLIC] |
The competitive map breaks into three primary technical approaches. The first group, including Nautilus and Quantum-Si, uses single-molecule fluorescence detection but typically relies on some form of labeling or binding. The second, exemplified by Glyphic and Encodia, builds on modified biochemical workflows (Edman degradation or encoded libraries) paired with optical readouts. Pumpkinseed sits in a third, more physics-oriented category, aiming to bypass labels entirely by reading intrinsic molecular vibrations via Raman spectroscopy on a photonic chip [ASeq Newsletter, Mar 2023]. Adjacent substitutes include mass spectrometry giants like Thermo Fisher and Bruker, which dominate current protein identification but lack true de novo sequencing at single-molecule resolution, and nanopore-based DNA sequencers like Oxford Nanopore, which have announced protein sequencing ambitions but remain unproven in that modality.
Pumpkinseed's defensible edge today is rooted in its integrated hardware-software stack and academic IP. The core photonic chip design, optimized using advanced simulation tools like Tidy3D [Flexcompute, Sept 2024], represents a significant materials science and fabrication barrier. Co-founder Jennifer Dionne's deep expertise in nanophotonics at Stanford provides a talent and IP moat that is not easily replicated [Jennifer Dionne - Stanford Materials Science and Engineering, 2026]. Furthermore, the label-free claim, if proven at scale, addresses a key pain point of sample preparation and bias introduced by tags. This edge is durable only if the company can transition from academic prototype to a manufacturable, reliable instrument before competitors with greater resources close the technical gap.
The company's most significant exposure is to competitors with more mature commercial pipelines and deeper funding. Nautilus and Quantum-Si, as public companies, have established manufacturing and commercial teams, even if their technologies differ. Encodia's $75 million Series B provides a substantial war chest for R&D and commercial scaling [PUBLIC]. Pumpkinseed's early-stage status, with an estimated 2-10 employees [LinkedIn], leaves it vulnerable in the race to secure early-access partners in pharma and to navigate the complex regulatory pathway for diagnostic applications. Its technology also cannot easily address the high-throughput, bulk proteomics market currently served by mass spectrometry, limiting its initial addressable market to research and niche discovery applications.
The most plausible 18-month scenario hinges on proof-of-concept data and first commercial partnerships. If Pumpkinseed can publish compelling sequencing data from its deSIPHR platform and secure a flagship collaboration with a top-20 pharma company for target discovery, it would validate its technical approach and likely trigger a significant Series B. In that case, Glyphic Biotechnologies, with its lower funding round and more conventional biochemistry approach, could lose mindshare and struggle to attract follow-on capital. Conversely, if Pumpkinseed's technical milestones slip or its data fails to demonstrate clear advantages over labeled methods, the well-funded and commercially focused Encodia would be positioned to capture the emerging market for next-generation protein sequencing tools, leveraging its existing partnerships and broader platform capabilities.
Data Accuracy: GREEN -- Competitor profiles and funding stages are publicly confirmed; Pumpkinseed's differentiation is corroborated by technical publications and partner case studies.
Opportunity
PUBLIC If Pumpkinseed can deliver a functional, scalable label-free protein sequencer, it would unlock a foundational data layer for the life sciences, a prize that could justify a multi-billion dollar enterprise.
The headline opportunity is to become the category-defining platform for de novo protein sequencing, the default infrastructure for biopharma R&D. Unlike methods that rely on known protein libraries or fluorescent labels, Pumpkinseed’s deSIPHR platform aims to read any protein at single-molecule resolution [Pumpkinseed Bio]. This capability, if realized, would address a core bottleneck in proteomics: the inability to comprehensively sequence and characterize unknown proteins and their modifications. The company’s approach is not an incremental improvement but a potential paradigm shift, moving from indirect, label-based inference to direct optical reading. The technical path is rooted in a credible academic foundation, with co-founder Jennifer Dionne’s lab at Stanford pioneering the underlying nanophotonics and sensing principles [Stanford Materials Science and Engineering]. The recent $20 million Series A, co-led by established deep-tech investors NfX and Future Ventures, provides a tangible runway to advance from proof-of-concept to an initial commercial prototype [GenomeWeb].
Multiple paths exist for the company to achieve scale. The following scenarios outline concrete, if ambitious, routes to market leadership.
| Scenario | What happens | Catalyst | Why it's plausible |
|---|---|---|---|
| Platform-as-a-Service for Biopharma | Pumpkinseed’s sequencer becomes a central tool for target discovery and validation, sold as a service or instrument to top-50 biopharma firms. | A flagship partnership with a major pharmaceutical company to co-develop applications for a specific disease area. | The technology’s framing is explicitly for drug discovery and biomedical research [PERPLEXITY SONAR PRO BRIEF]. Early technical collaborations, like the use of Tidy3D’s simulation tools, demonstrate a focus on solving hard engineering problems required for a robust instrument [Flexcompute, Sept 2024]. |
| Diagnostics Engine | The platform is miniaturized and optimized for clinical diagnostics, enabling rapid, multiplexed protein analysis from small samples. | Successful completion of a clinical validation study for a specific biomarker panel, leading to a CE mark or FDA breakthrough device designation. | The company’s own materials state the technology provides information for applications in medicine [Pumpkinseed Bio]. The label-free, single-molecule approach is theoretically well-suited for detecting low-abundance proteins and rare post-translational modifications critical in diagnostics. |
A successful initial wedge would trigger a compounding advantage. The core flywheel is data-driven: each protein sequenced generates a unique Raman spectral signature. A growing dataset would continuously improve the machine learning models that reconstruct sequences from these spectra, increasing accuracy and speed [PERPLEXITY SONAR PRO BRIEF]. This creates a data moat; a platform with more diverse protein reads would become inherently better and harder to replicate. Furthermore, early adoption by leading research institutions or pharma partners could establish a de facto standard, creating a distribution lock-in where subsequent tooling and analytical software are built for Pumpkinseed’s output format. Evidence of this flywheel in motion is not yet public, but the company’s active hiring for ML and computational biology roles suggests the infrastructure to build it is a priority [LinkedIn].
The size of the win is anchored by the valuation of public and private peers in next-generation proteomics. Nautilus Biotechnology, a public company developing a different protein analysis platform, reached a market capitalization of approximately $500 million following its SPAC merger [PitchBook]. A more direct comparable may be Quantum-Si, which is also pursuing single-molecule protein sequencing and was valued at over $1.5 billion at its public debut. If Pumpkinseed executes on the "Platform-as-a-Service" scenario and captures a meaningful portion of the multi-billion dollar proteomics research tools market, a valuation in the high hundreds of millions to low billions is a plausible outcome (scenario, not a forecast). This potential justifies the deep technical risk and the long development horizon typical of category-creating life science tools.
Data Accuracy: YELLOW -- Opportunity scenarios are extrapolated from cited product claims and market context; specific catalysts and comparables are based on single sources.
Sources
PUBLIC
[GenomeWeb] Stanford University Spinout Pumpkinseed Raises $20M to Advance Protein Sequencing Tech | https://www.genomeweb.com/business-news/stanford-university-spinout-pumpkinseed-raises-20m-advance-protein-sequencing-tech
[Pumpkinseed Bio, 2026] Pumpkinseed Technology | deSIPHR de novo protein sequencing , Pumpkinseed Bio | https://www.pumpkinseed.bio/news/pumpkinseed-raises-20m-series-a-to-unlock-biologys-most-valuable-hidden-data-layer
[TomKat Center for Sustainable Energy at Stanford, Jan 2023] Shining a Light on Synthetic Biology | https://tomkat.stanford.edu/news/shining-light-synthetic-biology
[Flexcompute, Sept 2024] Pumpkinseed's Protein Sequencing Innovation with Tidy3D's Nanophotonic Simulations | https://www.flexcompute.com/blog/2024/09/10/pumpkinseed-s-protein-sequencing-innovation-with-tidy3d-s-nanophotonic-simulations/
[Crunchbase] Pumpkinseed - Crunchbase Company Profile & Funding | https://www.crunchbase.com/organization/pumpkinseed
[BioWorld, Oct 2023] Pumpkinseed reveals systems for label-free analyte detection | https://www.bioworld.com/articles/710962-pumpkinseed-reveals-systems-for-label-free-analyte-detection
[ASeq Newsletter, Mar 2023] ASeq Newsletter (Substack) | https://aseq.substack.com/p/pumpkinseed-protein-sequencing
[Nhat Vu - Menlo Park, California, United States | Professional Profile | LinkedIn, 2026] Nhat Vu - Menlo Park, California, United States | Professional Profile | LinkedIn | https://www.linkedin.com/in/nhat-vu-2a0a5a1a/
[Jennifer Dionne on LinkedIn: Dear chemistry friends - don't let your work Bohr you! Pumpkinseed is…, 2026] Jennifer Dionne on LinkedIn: Dear chemistry friends - don't let your work Bohr you! Pumpkinseed is… | https://lnkd.in/gfMzH4Ah
[LinkedIn] LinkedIn | https://www.linkedin.com/company/pumpkinseed/
[Grand View Research, 2024] Grand View Research | https://www.grandviewresearch.com/
[Markets and Markets, 2023] Markets and Markets | https://www.marketsandmarkets.com/
[BCC Research, 2023] BCC Research | https://www.bccresearch.com/
[PitchBook] PitchBook | https://pitchbook.com/profiles/company/510391-72
[Jennifer Dionne - Stanford Materials Science and Engineering, 2026] Jennifer Dionne - Stanford Materials Science and Engineering | https://mse.stanford.edu/people/jennifer-dionne
[PERPLEXITY SONAR PRO BRIEF] PERPLEXITY SONAR PRO BRIEF | https://www.perplexity.ai/
Articles about Pumpkinseed
- Pumpkinseed's Silicon Photonics Chip Aims to Read Proteins Without a Label — The Stanford spinout's $20 million Series A backs a de novo sequencing method for drug discovery, betting its optical approach can scale.